Comparative PK? [Study Per­for­mance]

posted by PVRC – India, 2021-05-12 15:48 (39 d 17:22 ago) – Posting: # 22346
Views: 446

Hi Helmut,

Thank you for the reply..,

» » […] the agency …
»
» May I ask: Which agency?

The FDA

» … recommend to demonstrate comparative PK in the absence of bioequivalence.
»
» Do I get you right: The study was planned to demonstrate BE, failed, and now you were asked about ‘comparative PK’? I never came across such a term.

The following is the guidance....

To use pharmacokinetics (PK) bridging only, you should establish bioequivalence between test drug the listed drug under both fasting and fed conditions.

If the bioequivalence cannot be established due to different food effect or other reasons, you should demonstrate comparable PK and pharmacodynamics (PD) between Test and reference.

To establish "comparable PK" between test and reference, the active drug exposure (AUC, Cmax and Ctrough) of test at the proposed dosing regimen should be comparable with the listed drug.

Thanks

Complete thread:

Activity
 Admin contact
21,530 posts in 4,499 threads, 1,524 registered users;
online 7 (0 registered, 7 guests [including 5 identified bots]).
Forum time: Monday 09:11 CEST (Europe/Vienna)

Young man, in mathematics you don’t understand things.
You just get used to them.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5